Myeloid Mutations Register in R/R CML

Grupo Cooperativo de Hemopatías Malignas29 enrolled

Overview

The aim of the study is to know the percentage of ABL mutations in patients with chronic myeloid leukemia that relapsed or are refractory to tyrosine-kinase inhibitors measured with a myeloid mutations panel by NGS.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Chronic Myeloid Leukaemia Recurrent Chronic Myeloid Leukemia, in Relapse

Interventions

Myeloid mutations measurementDIAGNOSTIC_TEST

Measure of myeloid mutations by NGS when detection of refractory or relapsed CML is done

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * CML diagnosis by the WHO 2016 criteria * Failure to reach cytogenetic response of Ph chromosome of 36 to 95% at 3 months or BCR/ABL \<10% at 6 months of treatment with TKI * Progression or relapse of the disease after previous response to treatment with TKI * Validation of adherence to treatment * Inform consent Exclusion Criteria: * Lack of information to complete the register * Failure to response achievement due lack of adherence to treatment

Locations (1)

Grupo Cooperativo de Hemopatías Malignas

Huixquilucan, State of Mexico, Mexico

RECRUITING

Outcomes

Primary Outcomes

Presence of myeloid mutations by Next Generation Sequence

Detection of positive myeloid mutations at detection of relapse or refractoriness to ITK treatment

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.